Australia's Immuron gains as Q3 sales more than triple
** Shares of Immuron Ltd IMC.AX rise as much as 24.3% to
A$0.087, set for their best day since Dec. 29, 2022, if gains
hold
** Biopharmaceutical co says global sales for third quarter
FY23 more then tripled to A$1.46 mln ($0.9785)
** Says sales in U.S. are anticipated to increase
** IMC at its highest level since Dec. 30, 2022
** Stock down ~19% YTD, as of last close
($1 = 1.4921 Australian dollars)
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million